Safety, Efficacy, and Clinical Outcomes of APRV in ARDS: A Systematic Review and Meta-Analysis

ratios on Days 1 and 3, and was associated with shorter ICU length of stay and more ventilator-free days compared with conventional ventilation. Plateau pressures were also notably reduced at Days 3 and 7, suggesting a lung-protective effect. However, no significant differences were observed in ICU or hospital mortality, total ventilator duration, or overall hospital length of stay.ConclusionThese findings imply that APRV is able to enhance early oxygenation and improve ICU-related outcomes in ARDS without increasing mortality risk. While its physiologic advantages and potential lung-protective characteristics support its use as a viable alternative ventilation strategy, further large-scale trials are needed to confirm these findings and define optimal implementation protocols.